News from the CGRP Forum

ACHIEVE II meets primary endpoints with ubrogepant 50mg in acute migraine treatment

Significantly more migraine patients were free of pain and the most bothersome migraine symptoms, two hours after taking the oral CGRP inhibitor, ubrogepant 50mg, than those treated with placebo. These were the key findings reported by investigators taking part in the Phase 3, ACHIEVE II trial.

Read the full report here »